Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01269801 · ClinicalTrials.gov registry record · Phase 4

Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds

A Phase 4 study of Wrinkles, sponsored by AboutSkin Dermatology and DermSurgery, PC.

Completed
Registry status
Phase 4
Development phase
156
Enrollment target
3
Study locations

NCT01269801 is a Phase 4 study of Wrinkles that has completed, run by AboutSkin Dermatology and DermSurgery, PC. The registered enrollment target is 156 participants, above the 34-participant average among 7 other Wrinkles trials with a reported enrollment target (359% higher). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01269801, a Phase 4 study of Wrinkles, has completed, sponsored by AboutSkin Dermatology and DermSurgery, PC.

COMPLETED
Registry status
Phase 4
Development phase
156 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to see how well Juvederm Ultra XC or Juvederm Ultra Plus XC, and BOTOX Cosmetic, work compared to each other and when used together for the cosmetic treatment of age-associated wrinkles and folds of the face.

Conditions Studied

Interventions

  • DRUG onabotulinumtoxinA
  • DRUG JUVÉDERM

Study Locations (3)

Ontario

  • Niagara Falls Dermantology and Skin Care Center - Niagara Falls
  • University of Toronto - Toronto

Colorado

  • About Skin Dermatology - Englewood

Trial Details

FieldValue
Enrollment Target 156 participants
Start Date 2011-01
Est. Completion 2012-02
Phase Phase 4

What the Registry Record Tells You About NCT01269801

The ClinicalTrials.gov registry entry for NCT01269801 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 34-participant average among 7 other Wrinkles trials with a reported enrollment target (359% higher). The listed sponsor is AboutSkin Dermatology and DermSurgery, PC, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Wrinkles appearing as the primary indexed condition, and to 2 interventions - of which onabotulinumtoxinA is the first listed.

NCT01269801 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Ontario, Colorado.

Frequently Asked Questions

What is clinical trial NCT01269801 about?

NCT01269801 is a clinical study titled "Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds". The purpose of this study is to see how well Juvederm Ultra XC or Juvederm Ultra Plus XC, and BOTOX Cosmetic, work compared to each other and when used together for the cosmetic treatment of age-associated wrinkles and folds of the face.

What is the current status of trial NCT01269801?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 156 participants. The study started on 2011-01. Estimated completion is 2012-02.

What conditions does trial NCT01269801 study?

This clinical trial studies the following conditions: Wrinkles.

What interventions are being tested in trial NCT01269801?

The interventions under investigation include: onabotulinumtoxinA (DRUG), JUVÉDERM (DRUG).

Who is sponsoring clinical trial NCT01269801?

This trial is sponsored by AboutSkin Dermatology and DermSurgery, PC, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01269801 being conducted?

This trial has 3 study locations across Colorado, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Wrinkles

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.